Novel compounds in the therapy of breast cancer: Opportunities for integration with docetaxel

Oncologist

Volumn 6, Issue SUPPL. 3, 2001, Pages 40-44

  Tolcher, Anthony W ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Bcl 2 antisense oligonucleotides; Docetaxel; Farnesyl transferase inhibitors; Tyrosine kinase inhibitors

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTISENSE OLIGONUCLEOTIDE; CANERTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; G 1319; GEFITINIB; L 778123; LONAFARNIB; MONOCLONAL ANTIBODY; OSI 358 774; PELITINIB; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RI 15777; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER INHIBITION; CANCER REGRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035026010     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_3-40     Document Type: Conference Paper

References (54)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. The neu oncogene encodes an epidermal growth factor receptor-related protein
3. The product of the cerbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
4. Localization of the human cerb-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32
5. Neu-protein overexpression in breast cancer. Association with comedotype ductal carcinoma in situ and limited prognostic value in stage II breast cancer
6. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
7. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
8. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for the treatment of primary breast cancer
9. ErbB tyrosine kinase and the two neuregulin families constitute a ligandreceptor network
10. HER antibody for human cancer therapy
11. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumor cell growth
12. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo
13. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo
14. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
15. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for the treatment of human breast cancer
16. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
17. +/MBC) markedly increases activity: A randomised, multinational controlled phase III trial
18. Receptor proteintyrosine kinases and their signal transduction pathways
19. Diversification of Neu differentiation factors and epidermal growth factor signalling by combinatorial receptor interactions
20. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulins and epidermal growth factor
21. Neuregulins and their receptors: A versatile signalling module in organogenesis and oncogenesis
22. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu over-expressing human breast cancer xenografts
23. Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD- 1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
24. Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development
25. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
26. Combinatorial chemoprevention of intestinal neoplasia
27. ZD1839, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor: First phase 1, pharmacokinetic (PK) results in patients
28. Concepts in Ras-directed therapy
29. Control of ras activation
30. GTPase activating proteins
31. Farnesyltransferase inhibitors. Preclinical development
32. RAS inhibitors: Potential for cancer therapeutics
33. Ras-induced cellular events
34. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
35. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
36. Inhibitors of Ras farnesyltransferases
37. The farnesyl transferase inhibitor SCH 66336 induces a G(2)→M or G(1) pause in sensitive human tumor cell lines
38. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
39. (+)-4-[2-[4-(8Chloro-3,10-dibromo-6,11 -dihydro-5H-benzo[5, 6] cyclohepta[1,2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1 -piperidinecarboxamide (SCH-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent
40. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
41. A phase II study of the farnesyl transferase inhibitor R1 15777 in patients with advanced breast cancer
42. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to Taxol and epothilones
43. G(1) phase-dependent expression of bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells
44. p53 Mediates bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNKl pathway
45. Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines
46. Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo
47. New anticancer molecules: Drugs for tomorrow?
48. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides
49. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
50. Promise and problems of Bcl-2 antisense therapy
51. Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans Retinamide
52. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus Taxol after castration in the Shionogi tumor model
53. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
54. A phase I study of bcl-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors